# Cardiology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Franklin D. Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET002-SYN-TD
- Date: 1944-03-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Brooks, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Miriam Castellanos, MD, Cardiology
- Urgency: Routine, within two weeks; echocardiogram booked for the morning of the consultation

## Referral question

New heart failure, probably with reduced ejection fraction and driven by severe hypertension, in a 62-year-old man who smokes and uses a wheelchair. Please review the echocardiogram, confirm the diagnosis and its likely cause, and guide titration of guideline-directed therapy. **S**

## Questions for the consultant

1. Does the echocardiogram confirm heart failure with reduced ejection fraction, and is hypertension a sufficient explanation, or is an ischemic evaluation needed first?
2. Do you agree with starting all four drug classes at low doses, adding spironolactone after the two-week potassium check, and the order of up-titration?
3. Should his iron deficiency be treated with intravenous iron?
4. When should the echocardiogram be repeated, and what would make him a candidate for device therapy?
5. Is cardiac rehabilitation appropriate for a wheelchair user, and when?

## Pertinent history

Breathlessness after propelling his wheelchair short distances, orthopnea, and leg swelling that is cutting short his workdays; NYHA class III. Blood pressure 186/108 mmHg, pulse 96, oxygen saturation 93 percent. NT-proBNP 2850 pg/mL, potassium 4.2 mmol/L, creatinine 1.18 mg/dL (eGFR 70), urine albumin-creatinine ratio 64 mg/g, LDL cholesterol 132 mg/dL, HbA1c 5.9 percent, TSH normal. Hemoglobin 12.6 g/dL with ferritin 48 ng/mL and transferrin saturation 16 percent. About a pack of cigarettes a day for more than thirty years; he has set a quit date. Paraplegic since a paralytic illness at age 39; independent in transfers. Started today: sacubitril/valsartan 24/26 mg twice daily, carvedilol 3.125 mg twice daily, empagliflozin 10 mg daily, furosemide 20 mg daily, atorvastatin 40 mg daily, and a 21 mg nicotine patch. **S**

- Franklin Delano Roosevelt was born on January 30, 1882, at Springwood, the family's estate in Hyde Park, New York. **D**
- In the summer of 1921 Roosevelt developed a paralytic illness at Campobello; on August 25, 1921, Dr. Robert Lovett diagnosed infantile paralysis (polio), and Roosevelt remained paraplegic, using leg braces from early 1922. **D**
- A 2003 Bayesian analysis of the recorded symptoms concluded that Guillain-Barré syndrome was more probable than paralytic polio as the cause of Roosevelt's 1921 illness; the conclusion is disputed and cannot be confirmed because no cerebrospinal fluid was examined. **R**
- In May 1941 Roosevelt had severe iron deficiency anemia, with hemoglobin reported at 4.5 g/100 mL. **D**
- At an examination at Bethesda Naval Hospital on March 27, 1944, Roosevelt's blood pressure was 186/108; he was breathless and cyanotic with rales, and X-rays and an electrocardiogram showed an enlarged heart, congestive heart failure, and a mitral murmur. His blood pressure had not been checked since February 27, 1941. **D**
- After the March 1944 examination Roosevelt was treated with digitalis, a low-sodium and weight-reduction diet, and rest; his working hours were reduced, his cigarettes were limited to ten a day, and his evening cocktails were reduced. **D**
- Roosevelt's father, James Roosevelt, died in 1900 during Franklin's first term at Harvard; his mother, Sara Delano Roosevelt, died at Springwood in September 1941. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: NT-proBNP: 2850 pg/mL (high); Sodium: 137 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 1.18 mg/dL; eGFR: 70 mL/min/1.73 m²; Glucose: 104 mg/dL (high); Hemoglobin: 12.6 g/dL (low); Ferritin: 48 ng/mL; Transferrin saturation: 16% (low); TSH: 2.1 mIU/L; LDL cholesterol: 132 mg/dL (high); HbA1c: 5.9% (high); Urine albumin-creatinine ratio: 64 mg/g (high); KCCQ-12 overall summary: 38; PHQ-2: 1. All results are synthetic.

BP 186/108 mmHg; pulse 96 bpm; respirations 22/min; temperature 36.9 °C; oxygen saturation 93% on room air; weight 88 kg; BMI 24.9 kg/m². All vital signs are synthetic.

## Current medications

- Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily **S**
- Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Nicotine 21 mg/24 hr transdermal patch, apply one patch daily **S**

## Plan so far

- Start guideline-directed therapy for HFrEF: sacubitril/valsartan, carvedilol, and empagliflozin, with furosemide for congestion; add spironolactone after the two-week potassium check. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) **S**
- Check a basic metabolic panel one to two weeks after each renin-angiotensin or mineralocorticoid antagonist change, then every three to six months when stable. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026) **S**
- Treat to a blood pressure below 130/80 with home blood pressure and daily weight logs; low-sodium diet. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026) **S**
- Tobacco cessation counseling with nicotine replacement and a quit date. Guideline: Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**
